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2Abstract 
Full understanding of the barrier property of mucosal tissues is imperative for development of 
successful mucosal drug delivery strategies, particularly for biologics and nanomedicines. The 
contribution of the mucosal basement membrane (BM) to this barrier is currently not fully 
appreciated. This work examined the role of the BM as a barrier to intestinal absorption of model 
macromolecules (5 kDa and 10 kDa dextrans) and 100 nm polystyrene nanoparticles. Dextrans and 
nanoparticles were applied either directly to BM-coated inserts or to an intestinal model, namely 
differentiated intestinal epithelial monolayers (Caco-2) cultured on BM-modified inserts. The work 
shows that the BM per se does not impact the diffusion of dextran macromolecules, but severely 
hinders the movement of nanoparticles. However, importantly, Caco-2 monolayers cultured on BM-
coated inserts, which show a remarkably different morphology, display a significantly larger barrier 
to the translocation of one dextran, as well as nanoparticle systems compared to cells cultured on 
unmodified inserts. Therefore, this work shows that in addition to presenting a direct physical 
barrier to the movement of nanoparticles, the BM also exerts an indirect barrier effect, likely due to 
its influence on epithelial cell physiology. This work is important as it highlights the currently unmet 
need to consider and further study the barrier properties of the BM in mucosal delivery of biologics 
and nanomedicines.
Key words: Basement membrane, Biologics delivery, Caco-2 cells, Intestinal absorption, 
Nanomedicine
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31 Introduction 
2 Biologics and nanomedicines as complex therapeutics are currently almost exclusively administered 
3 by injection. Non-invasive delivery is preferred over injections due to patient convenience, 
4 elimination of injection-associated side effects and, potentially, reduced costs (1, 2). While mucosal 
5 administration is currently not a viable option for systemic delivery of most of these advanced 
6 therapeutics – mainly due to the challenge of overcoming the mucosal barriers – research into this 
7 field is progressing at a fast pace. This is fuelled by the proliferation and wider clinical use of these 
8 therapeutics, as well as advances in drug delivery technologies. Development of successful drug 
9 delivery technologies enabling mucosal administration of biologics and nanomedicines for systemic 
10 effect relies on comprehensive understanding of mucosal barriers. 
11
12 Mucosal tissues are structurally organised so to serve the important role of a barrier to systemic 
13 entry of material from the external environment. The multiple constituent elements of mucosal 
14 tissues that present barriers to drug delivery include mucus, enzymes, epithelium and the basement 
15 membrane (BM). The epithelium is considered to be the principal mucosal barrier component to 
16 systemic absorption of complex therapeutics such as macromolecules nanomedicines. Mucus has 
17 also been shown to hinder the diffusion of some macromolecules and many nanoparticles (3). 
18 However, effective drug delivery strategies now exist to promote the diffusion of nanomaterials in 
19 mucus (e.g. via the ‘PEGylation’ approach) (4-7) and also facilitate their translocation across the 
20 epithelial barrier (e.g. by exploiting epithelial transcytosis to shuttle material across the epithelium) 
21 (8, 9). On the other hand, the BM barrier has not been fully characterised. With an increasing 
22 proliferation of biologics and nanomedicines and efforts to achieve non-invasive delivery of these 
23 therapeutics, there is a need to characterise the barrier properties of the BM to systemic absorption 
24 of these therapeutics across mucosal surfaces.
25
26 BMs are thin, specialised sheets of extracellular matrices found between epithelia and connective 
27 tissue in the human body (10, 11). Collagen is the main protein of the extracellular matrix (ECM) and 
28 is linked by multiple bonds, including disulphide and hydrogen bonding, that gives tensile strength to 
29 BM (12, 13). Alongside collagen, laminin, which strongly associates to the cell surface, provides 
30 additional organised structural support to the BM (14). BMs have several roles including the 
31 regulation of cell adhesion, differentiation and motility (15). BM also serves a filter function due to 
32 its selective passage of molecules across its barrier (16). 
33
34 In this work, we characterised the BM barrier by probing its effect in isolation as a direct barrier to 
35 the diffusion of model macromolecules and nanoparticles. Importantly, we also incorporated the BM 
36 in a commonly utilised cell culture model of the intestinal epithelium (Caco-2 monolayers) and 
37 studied the barrier property of the resulting system in order to ascertain whether the BM may have 
38 additional, indirect barrier effects by potentially influencing epithelial cell physiology. 
39 Materials and Methods 
40 Basement membrane extract (BME, commercially known as Cultrex® Pathclear®) was purchased 
41 from Trevigen (Gaithersburg, MD). Hank’s Balanced Salt Solution (HBSS) modified with sodium 
42 bicarbonate, without phenol red and fluorescein isothiocyanate (FITC)-labelled dextrans of average 
43 molecular weights of 4 and 10 kDa (FD4 and FD10, respectively) were purchased from Sigma-Aldrich 
44 (Poole, UK). Transwell® polycarbonate permeable inserts of 12 mm diameter and 0.4 µm pore size 
45 and black 96-well assay plates were purchased from Corning (Corning, NY). Caco-2 cells were 
46 purchased from the European Collection of Cell Cultures (ECACC) and used between passages 64-73. 
47 Dulbecco’s Modified Eagles Medium (DMEM) with 4500 mg/L glucose, L-glutamine, sodium pyruvate 
48 and sodium bicarbonate, trypsin/EDTA solution, antibiotic/antimycotic solution (penicillin, 
49 streptomycin and amphotericin) and foetal bovine serum (FBS, non-USA origin) were all obtained 
50 from Sigma-Aldrich (Poole, UK). DMEM was supplemented with 10% v/v Foetal Bovine Serum (FBS) 
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451 and 1% v/v antibiotic/antimycotic solution. Fluorescent sulfate- and amine-modified polystyrene 
52 nanoparticles of 100 nm diameter were also purchased from Sigma-Aldrich (Poole, UK). For 
53 immunostaining analysis, paraformaldehyde, Triton X-100, bovine serum albumin (BSA) and 4’,6-
54 diamidino-2-phenylindole (DAPI) were purchased from Sigma-Aldrich (Poole, UK). Anti-human 
55 zonula occludens rabbit antibody (ZO-1) was obtained from Zymed, Cambridge Bio Science 
56 (Cambridge, UK). Alexa Fluor 488 chicken anti-rabbit IgG was purchased from ThermoFisher 
57 Scientific (Loughborough, UK). 
58
59 Preparation of BM-coated inserts
60 Transwell inserts were coated with BME following the manufacturer’s protocol for the ‘thin layer 
61 method’. Briefly, BME was thawed and mixed by slowly pipetting the solution up and down, avoiding 
62 the introduction of air bubbles. Freshly-thawed BME was then diluted in cold HBSS to achieve a 
63 protein concentration of approximately 150 µg/ml. 330 µl of this solution (300 μl/cm2) was applied 
64 to the insert and allowed to incubate at room temperature for one hour. Excess BME was removed, 
65 leaving a thin layer of material on the inserts. Coated surfaces were not allowed to dry out, with 
66 diffusion studies or cell plating performed immediately after the coating procedure. 
67
68 Permeability of dextrans and nanoparticles across BM 
69 Freshly prepared, BM-coated Transwell® inserts were utilised for these studies, with uncoated 
70 inserts serving as a control. HBSS (1.5 mL), pre-warmed to 37°C, was placed in the acceptor (basal) 
71 compartment and 500 µl of dextran solutions or nanoparticle suspensions in HBSS were added to 
72 the donor (apical) compartments. FD4, FD10 and nanoparticles were applied at 100 µg/ml. Basal 
73 solution (100 µl) was sampled at 20-minute intervals for two hours, with the replacement of 
74 sampled solutions with fresh HBSS. Dextran and nanoparticle permeabilities were quantified by 
75 fluorescence. 
76
77 Cell culture 
78 Caco-2 cells were routinely cultured on T75 flasks using DMEM. Cells were seeded on unmodified or 
79 BM-coated inserts at 105 cells/cm2. Culture medium was replaced three times per week. Caco-2 cells 
80 were typically cultured on inserts for 21–23 days, prior to their use in permeability studies, with 
81 measurement of transepithelial electrical resistance (TEER), using a Millicell ERS-2 voltohmmeter 
82 obtained from Millipore (Burlington, MA), to confirm cell monolayer integrity. 
83
84 Permeability of dextrans and nanoparticles across BM-cultured Caco-2 monolayers 
85 Caco-2 cells were cultured on inserts coated with BM, following the methodologies described above. 
86 After a minimum 21-day culture, cell monolayer TEER was measured to confirm epithelial barrier 
87 integrity and suitability for permeability studies. Culture medium was replaced with HBSS (pre-
88 warmed to 37°C), which was used as a transport medium in these studies; cells were equilibrated in 
89 HBSS for approximately 45 min. Dextrans and nanoparticles were applied to the apical side of cell 
90 monolayers at 100 µg/ml in HBSS. Basal solution (100 µl) was sampled every 20-minutes for two 
91 hours, with sampled solutions replaced with fresh HBSS. Apical-to-basal permeability of dextrans 
92 and nanoparticles was quantified by fluorescence. 
93
94 Effect of BM culture on cell monolayer TEER 
95 Caco-2 cells were seeded on inserts that were freshly coated with BM (as described above) or 
96 uncoated inserts. TEER was measured at regular intervals during a 21-day culture for both 
97 conditions. 
98
99 Calculation of apparent permeability coefficient (Papp) 
100 The permeability of FITC-dextrans and nanoparticles is expressed as the apparent permeability 
101 coefficient (Papp), calculated using this equation:
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5102
103  
104
105
106 where Papp = apparent permeability in cm/s, ∆Q/∆t is the permeability rate (amount of material 
107 permeating over time), A is the diffusion area of the insert or cell monolayer (cm2) and Co is the 
108 initially applied material concentration.  
109
110 Cell immunostaining for zonula occludens-1 (ZO-1)
111 Polarized Caco-2 monolayers were washed with PBS and fixed with paraformaldehyde (4% w/v) on 
112 ice for 20 min. Cells were washed with PBS again and permeabilized with Triton X-100 (0.05% v/v in 
113 PBS) for 5 min. Cells were re-washed with PBS, followed by washing with BLOTTO (5% instant non-
114 fat dry milk in 10 mM PBS), and subsequently incubated overnight at 4 °C with rabbit, anti-human 
115 zonula occludens-1 (ZO-1) diluted in 1% w/v BSA/BLOTTO to 12 µg/ml. Cells were then washed 
116 extensively with PBS and treated with AlexaFluor 488-labelled chicken, anti-rabbit IgG (diluted in 1% 
117 w/v BSA/BLOTTO to a final concentration of 10 µg/ml) for 1 h at room temperature. Following this, 
118 cell monolayers were washed and filters excised and mounted on a microscope slide using a 4’,6-
119 diamidino-2-phenylindole (DAPI)-containing ProLong® Gold antifade reagent. Slides were stored at 
120 4°C and imaged within a week using a Nikon Eclipse Ti-E inverted confocal microscope (Nikon 
121 Instruments, UK). 
122
123 Effect of BM culture on cell size 
124 Freshly prepared, BM-coated Transwell® inserts were utilised for this study, with uncoated inserts 
125 serving as a control. Caco-2 cells were cultured on inserts coated with BM, following the method 
126 described above. After a minimum 21-day culture, cell monolayer TEER was measured to confirm 
127 epithelial barrier integrity and suitability for permeability studies. Culture medium was removed and 
128 cells were washed with PBS. Following this, PBS was replaced with trypsin/EDTA solution and 
129 incubated for 10 min at 37 °C. Caco-2 cells were detached from the polycarbonate membrane by 
130 gently tapping the inserts. Trypsin/EDTA solution was diluted with complete media and separated 
131 from the cells by centrifugation at 1,500 rpm for 5 min. Cells were re-suspended in media. Caco-2 
132 cells were mixed with tryphan blue (1:1) prior to counting on an automated cell counter (Countess II, 
133 Life Technologies, UK). 
134
135 Statistical analysis 
136 Student’s t-test was performed for comparisons of two group means, while one way analysis of 
137 variance (ANOVA) was utilised for comparison of three or more group means. Experiments were 
138 conducted in triplicates and repeated. P value of <0.05 was considered statistically significant. ** 
139 and * indicate p < 0.01 and p < 0.05, respectively, whereas “ns” indicates nonsignificant. Statistical 
140 analysis was conducted using GraphPad Prism® Software. 
141
142
143 Results 
144 Permeability of dextrans and nanoparticles across BM 
145 Permeation of FD4 and FD10 across BM-coated inserts is shown in Figure 1 (A and B, respectively). 
146 The data demonstrate that the permeability of both dextrans is not suppressed by BM coating of cell 
147 culture inserts (permeability was somewhat reduced but this was not statistically significant in both 
148 cases). 
149
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153 Figure 1. Dextran permeability across basement membrane. Apparent permeability (Papp) of dextran 
154 macromolecules of 4 kDa (FD4) (A) and 10 kDa (FD10) (B). Basement membrane-coated inserts denoted as 
155 ‘BM’, while unmodified inserts denoted as ‘uncoated’. FD4 and FD10 were applied in Hank’s Balanced Salt 
156 Solution (HBSS) at concentration 100 µg/ml. Data shown as the mean ± SD (n=3). 
157
158 Nanoparticle translocation across BM-coated inserts is shown in Figure 2. The data clearly 
159 demonstrate that BM-coating produces a notable reduction in the permeability of 
160 nanoparticles, by a factor of 2.6 and 2.3, for negatively- and positively-charged systems (2A 
161 and 2B), respectively. This therefore suggests that BM acts as a barrier to the translocation 
162 of 100 nm-sized, negatively-charged and positively-charged nanoparticles.  
163  
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166
167 Figure 2. Nanoparticle permeation across basement membrane. A) Negatively-charged 100 nm polystyrene 
168 nanoparticles. B) Positively-charged (amine-modified) 100 nm polystyrene nanoparticles. Basement 
169 membrane-coated inserts denoted as ‘BM’, while unmodified inserts denoted as ‘uncoated’. Nanoparticles 
170 were applied in Hank’s Balanced Salt Solution (HBSS) at concentration of 100 µg/ml. Data shown as the mean ± 
171 SD (n=3). 
172
173
174 Permeability of dextrans across BM-cultured Caco-2 monolayers 
175 The barrier properties of Caco-2 monolayers, cultured on BM-coated inserts, with respect to the 
176 permeation of FD4 and FD10 are shown in Figure 3. The data show that FD4 permeability is 
177 significantly reduced in BM-cultured cell monolayers compared to that across cells cultured on 
178 uncoated inserts (Figure 3A). This pattern however was not apparent for FD10, where culture of cells 
179 on BM-coated inserts did not have an effect on the extent of the barrier that the resulting epithelial 
180 monolayers present to this molecule (Figure 3B).   
181
182
183
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187 Figure 3. Effect of basement membrane culture on Caco-2 monolayer barrier to dextrans. A) Permeability of 
188 fluorescein isothiocyanate (FITC)-labelled dextran of average molecular weight 4 kDa (FD4). B) Permeability of 
189 FITC-labelled dextran of average molecular weight 10 kDa (FD10). Basement membrane-coated inserts 
190 denoted as ‘BM’, while unmodified inserts denoted as ‘uncoated’. FDs were applied in Hank’s Balanced Salt 
191 Solution (HBSS) at concentration 100 µg/ml. Data shown as the mean ± SD (n=3). 
192
193
194 Permeability of nanoparticles across BM-cultured Caco-2 monolayers 
195 Work examining the barrier capacity of BM-cultured Caco-2 cells towards the permeability of 
196 nanoparticles revealed that cell monolayers cultured in this manner markedly hindered the 
197 translocation of model nanoparticles (sulfate-modified systems were used in this experiment) 
198 markedly more than Caco-2 monolayers cultured on uncoated inserts (Figure 4). Specifically, 
199 nanoparticle translocation was approximately four times lower across intestinal epithelial Caco-2 
200 monolayers cultured in the presence of BM. 
201
202
BM Uncoated
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       **
203 Figure 4. Effect of basement membrane culture on the Caco-2 monolayer barrier to nanoparticles. Sulfate-
204 modified polystyrene nanoparticles of 100 nm diameter were used. Basement membrane-coated inserts 
205 denoted as ‘BM’, while unmodified inserts denoted as ‘uncoated’. Nanoparticles were applied in Hank’s 
206 Balanced Salt Solution (HBSS) at concentration of 100 µg/ml. Data shown as the mean ± SD (n=3). 
207
208
209 Effect of BM culture on cell monolayer TEER 
210 To better understand the effect of BM on the influence of the intestinal epithelial Caco-2 barrier, we 
211 conducted regular TEER measurements of cells cultured on BM-coated inserts throughout a 21-day 
212 culture period. The data in Figure 5 highlight that BM-coating had a significant impact on cell 
213 monolayer TEER. Notably higher TEER values in BM-cultured cells compared to cells grown on 
214 unmodified inserts were apparent throughout the entire culture period (all measurement points). 
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8215 This includes the early phase of culture with steep increase in TEER with time (up to day 10), as well 
216 as at a later phase of TEER plateau, which is typically seen with Caco-2 monolayer culture. 
217     
218
219 Figure 5. Effect of basement membrane on Caco-2 monolayer transepithelial electrical resistance (TEER). Cells 
220 were seeded on basement membrane coated inserts (‘BM’) or unmodified inserts (‘uncoated’). TEER was 
221 measured in culture medium at days 3, 6, 8, 10, 13, 15, 17, and 21. Data shown as the mean ± SD (n=12). 
222
223
224 Effect of BM culture on zonula occludens-1 (ZO-1)
225 As ZO-1 is a critical regulator of epithelial tight junctions and the resulting epithelial barrier and the 
226 BM showed clear effects on the Caco-2 monolayer barrier, we examined the influence of BM culture 
227 on Caco-2 ZO-1 protein expression and localisation. Figure 6 shows confocal micrographs of 
228 polarised Caco-2 cells grown on BM-coated (A) and uncoated (B) inserts. The data in Figure 6 reveal 
229 significant differences between the two conditions in terms of cell monolayer appearance. Caco-2 
230 cells cultured on BM-coated inserts appear to be significantly bigger, therefore occupying a larger 
231 area compared to cells grown on uncoated inserts. This is clearly apparent by the significantly lower 
232 number of cells (per equivalent area) that appear more spread out and with dramatically larger ZO-1 
233 staining circumference (typical ‘chicken wire’ appearance) on BM coated inserts (A), compared to 
234 the larger number of smaller cells, suggested by smaller ZO-1 perimeter, on uncoated inserts (B). 
235
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9236 A)    B)
237         
238
239 Figure 6. Caco-2 immunostaining for zonula occludens-1 (ZO-1) tight junction protein. Caco-2 cells were 
240 cultured for 21 days. Cells were incubated with rabbit, anti-human ZO-1 (primary) antibody, followed by 
241 AlexaFluor 488 chicken, anti-rabbit IgG (secondary antibody). Blue channel: cell nuclei stained with DAPI (4’,6-
242 diamidino-2-phenylindole); green channel: AlexaFluor (ZO-1 staining) fluorescence. A) Caco-2 monolayers 
243 cultured on BM-coated inserts. B) Caco-2 monolayers cultured on uncoated inserts. 
244
245 Effect of BM culture on cell size 
246 The difference in cell size between culture conditions employing BM and those without, as noted in 
247 confocal micrographs (Figure 6) was tested quantitatively. Data in Figure 7 show an average Caco-2 
248 cell size of 11.21 µm and 9.84 µm following culture on BM-coated (A) and uncoated inserts (B), 
249 respectively.
250
251 A)          B)
252    
253
254 Figure 7. Effect of basement membrane (BM) culture on cell size. A) Caco-2 monolayers cultured on BM-
255 coated inserts. B) Caco-2 monolayers cultured on uncoated inserts. 
256
257
258 Discussion 
259 Mucosally-administered drugs for systemic effect require satisfactory absorption from mucosal 
260 surfaces. This process also involves drug diffusion through the interstitum (after traversing the 
261 epithelium) into systemic circulation via capillary or lymphatic uptake. Factors that dictate mucosal 
262 (e.g. intestinal) absorption of small drug molecules are well established and have informed drug 
263 development (physicochemical requirements of drug molecules) for decades. 
264
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10
265 There are a number of physicochemical barriers operating at mucosal absorptive sites that 
266 potentially hinder drug absorption. While it is widely accepted that, in the case of intestinal drug 
267 absorption, the epithelium with its closely packed polarised cell structure is the key barrier and the 
268 limiting factor dictating systemic absorption of drug molecules, there is a need to characterise 
269 additional, non-epithelial mucosal barrier components. This is particularly the case with complex 
270 biotherapeutics and nanomedicines destined for mucosal administration because non-epithelial 
271 barriers may affect the systemic absorption of these therapeutics. As the clinical use of biologics and 
272 nanomedicines becomes more widespread, it is imperative that the mucosal barriers are fully 
273 understood to facilitate the development of successful drug delivery technologies for non-invasive 
274 (mucosal) administration of these therapies. 
275
276 While the diffusion of biomacromolecules and nanomedicines in the mucus barrier has been studied 
277 and strategies to overcome this barrier described (7, 17), it is currently unclear whether the BM, as a 
278 structure underneath the epithelium that must also be overcome for systemic absorption, hinders 
279 the diffusion of these materials. BM is specialised ECM and the latter has been shown to present a 
280 barrier to nanomaterials accessing the tumour compartment (18). For example, particles much 
281 smaller than the mesh size of ECM have been demonstrated to be immobilized in the ECM 
282 biopolymer matrix (19). This has significant implications for the design and fabrication of 
283 nanomedicines for mucosal delivery. 
284
285 We were first interested to study the barrier behaviour of the BM towards macromolecule diffusion. 
286 The data show that the BM per se did not hinder the diffusion of FD4 and FD10 (Figure 1) but 
287 decreased that of nanoparticles (Figure 2). These findings corroborate with studies in the area. For 
288 example, lining of a HeLa monolayer with BM followed by exposure to HPV-16 pseudoviruses 
289 reduced the percentage of infected HeLa cells by about 6-fold, highlighting the extent of the barrier 
290 that the BM presents to the movement of a 50 nm virus (20). 
291
292 While studies on the barrier properties of BMs of mucosal tissues relevant to drug administration 
293 are limited, much more is known about material diffusion in complex 3D biological environments, 
294 including ECM (21-23). It is appreciated that the complex ECM environment presents a major barrier 
295 that potentially limits the therapeutic success of nanomedicines (23). The mobility of the materials 
296 diffusing in ECM is restricted by both its pores and electrostatic interactions with the 
297 network-forming ECM components, hence filtering process consist of both size and interaction 
298 filtering (23). Therefore, the mobility of diffusing particles in ECM is chiefly affected by 
299 hydrodynamic diameter and surface charge. In terms of interaction filtering, particle diffusion 
300 through the ECM is influenced by complex interaction via electrostatic and hydrophobic interactions. 
301 Although a net negative charge predominates (from sulphate- and carboxyl-rich 
302 glycosaminoglycans), ECM matrix carries both positively and negatively charged components. It is 
303 thought that the composition and complex cross-links between ECM macromolecular components 
304 are both critical for the filtering process (23). ECM was shown to dramatically suppress the diffusion 
305 of both positively and negatively charged particles that were significantly smaller than its mesh size 
306 (19). 
307
308 Our results derived from the studies incorporating BM into Caco-2 culture are interesting. The Caco-
309 2 intestinal in vitro model is based on cell culture directly on plastic porous substrates and lacks the 
310 ability to produce a BM (24, 25). However, the intestinal epithelium in vivo is supported by a BM, 
311 which not only plays an essential role in controlling a variety of epithelial phenomena – including cell 
312 attachment, growth, migration and differentiation (26-28) – but can also affect the mucosal barrier. 
313 This effect can arise directly by the BM acting as a physical barrier towards the diffusion of material 
314 into the subepithelial interstitium, as well as indirectly, through a BM effect on the morphology and 
315 physiology of the epithelium it supports.  
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316
317 We observed that the BM significantly altered the barrier properties of Caco-2 monolayers to one of 
318 the tested dextrans (Figure 3), as well as nanoparticles (Figure 4). It is interesting that while FD4 
319 permeability was reduced notably (by approximately a factor of four), no effect was observed for 
320 FD10. The mechanism behind this observation could be related to a BM effect on the paracellular 
321 permeability, with a larger proportion of FD4 more likely to traverse the epithelial monolayers by 
322 this route, as opposed to FD10 (29). Hence, any effect on the paracellular pathway barrier will show 
323 a larger influence on FD4 permeability. 
324
325 To further probe the influence of BM on the epithelial paracellular barrier, we studied the TEER vs 
326 time profile, as well as the morphology of paracellular barrier-controlling tight junctions of Caco-2 
327 cells cultured on BM-coated inserts. In terms of TEER, the data in Figure 5 demonstrate clearly that 
328 the presence of BM leads to Caco-2 monolayers with a more restrictive paracellular barrier (higher 
329 TEER throughout the culture period). Staining for the tight junction protein, ZO-1, revealed a striking 
330 difference in cell morphology, with BM-cultured cells appearing larger in size (Figure 6). This was 
331 also confirmed quantitatively via cell size measurements (Figure 7). 
332
333 The indirect effect of the BM on the epithelial barrier is unsurprising given that previous studies 
334 have shown that focal adhesions, formed at cell-matrix contact points, influence the development 
335 and maintenance of tight junctions via the actin cytoskeleton (30-33). There is established evidence 
336 that the interaction of epithelial cells with the BM via cell surface integrins influences the expression 
337 of TJ proteins (34, 35). Our findings related to the BM effect on cell morphology may explain the 
338 barrier properties of Caco-2 epithelial monolayers. Specifically, a polarised monolayer with larger 
339 epithelial cells, such as one cultured on BM-coated inserts, will have a smaller paracellular surface 
340 area compared to a monolayer with smaller cells cultured on the same substrate area. This may 
341 therefore explain the finding that FD4 but not FD10 (i.e. the compound more likely to utilise the 
342 paracellular route) displayed attenuated permeability across BM-cultured Caco-2 monolayers 
343 compared to control. 
344
345 Overall, this work demonstrates that the BM plays an important role as a barrier to mucosal delivery 
346 of macromolecules and nanomedicines. This barrier-influencing role of the BM arises via a direct 
347 effect of BM as a physical barrier to the diffusion of materials, likely to be the case for nanoparticle 
348 diffusion, or by an indirect effect on epithelial physiology (more likely to impact macromolecule 
349 absorption). 
350
351 Conclusion 
352 This study shows that BM acts as a drug delivery barrier for intestinal delivery of macromolecules 
353 and nanomedicines in different ways. Strategies for mucosal delivery of complex therapeutics should 
354 therefore address the BM, in addition to other mucosal tissue barrier components. Furthermore, 
355 research employing in vitro mucosal models to study and predict mucosal delivery of 
356 macromolecules and nanomedicines should consider the incorporation and recapitulation of this 
357 important mucosal barrier component to improve the predictive value of the model.
358
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